Jenny Pena Dias1, Johannes D Veldhuis2, Olga Carlson1, Michelle Shardell3, Chee W Chia3, Denise Melvin1, Josephine M Egan1, Shehzad Basaria4. 1. Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, United States, 21225. 2. Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, MN, United States. 3. Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, United States, 21225. 4. Section on Men's Health, Aging and Metabolism, Brigham and Women's Hospital Harvard Medical School, Boston, MA, United States, 02115. Electronic address: sbasaria@partners.org.
Abstract
Growth hormone is the major regulator of growth and body composition. Pulsatile GH secretion declines exponentially with age. Testosterone replacement is being increasingly offered to older men with age-related low testosterone. Testosterone administration has been shown to stimulate GH secretion. However, little is known about the effect of testosterone aromatization to estradiol on GH pulsatility and its impact on IGF-1 in older men. OBJECTIVE: This randomized controlled proof-of-concept trial investigated the relative effects of testosterone and estradiol on GH pulsatility and IGF-1 in older men with low testosterone. DESIGN:Thirty-seven men, ≥65years with total testosterone <350ng/dL were randomized to 5g transdermal testosterone gel (TT), 1mg oral aromatase inhibitor (AI) or placebo daily for 12months. Primary outcome was deconvolution and approximate entropy analyses of pulsatile including basal and entropic modes of secretion performed at baseline and 3months. Secondary outcomes included IGF-1 evaluated at baseline, 3 and 6months. RESULTS: At 3months, mean GH and in IGF-1 were similar between the three groups. At 6months, IGF-1 significantly increased by Δ 15.3±10.3ng/ml in the TT-group compared to placebo (P=0.03). Both intervention groups significantly increased GH pulse frequency (TT-group, P=0.04; AI-group, P=0.05) compared to placebo. The GH secretory-burst mode (duration) significantly decreased in the TT-group (P=0.0018) compared to placebo while it remained unchanged in the AI-group (P=0.059). CONCLUSIONS: In older men, testosterone increases GH pulse frequency while the aromatization to estradiol is involved in the rise of IGF-1 levels.
RCT Entities:
Growth hormone is the major regulator of growth and body composition. Pulsatile GH secretion declines exponentially with age. Testosterone replacement is being increasingly offered to older men with age-related low testosterone. Testosterone administration has been shown to stimulate GH secretion. However, little is known about the effect of testosterone aromatization to estradiol on GH pulsatility and its impact on IGF-1 in older men. OBJECTIVE: This randomized controlled proof-of-concept trial investigated the relative effects of testosterone and estradiol on GH pulsatility and IGF-1 in older men with low testosterone. DESIGN: Thirty-seven men, ≥65years with total testosterone <350ng/dL were randomized to 5g transdermal testosterone gel (TT), 1mg oral aromatase inhibitor (AI) or placebo daily for 12months. Primary outcome was deconvolution and approximate entropy analyses of pulsatile including basal and entropic modes of secretion performed at baseline and 3months. Secondary outcomes included IGF-1 evaluated at baseline, 3 and 6months. RESULTS: At 3months, mean GH and in IGF-1 were similar between the three groups. At 6months, IGF-1 significantly increased by Δ 15.3±10.3ng/ml in the TT-group compared to placebo (P=0.03). Both intervention groups significantly increased GH pulse frequency (TT-group, P=0.04; AI-group, P=0.05) compared to placebo. The GH secretory-burst mode (duration) significantly decreased in the TT-group (P=0.0018) compared to placebo while it remained unchanged in the AI-group (P=0.059). CONCLUSIONS: In older men, testosterone increases GH pulse frequency while the aromatization to estradiol is involved in the rise of IGF-1 levels.
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Catalina Norman; Nanette L Rollene; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: Eur J Endocrinol Date: 2013-11-29 Impact factor: 6.664
Authors: Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; Adenborduin Adeniji; John M Miles; Remberto Paulo; Mihaela Cosma; Cacia Soares-Welch Journal: J Clin Endocrinol Metab Date: 2008-11-04 Impact factor: 5.958
Authors: Johannes D Veldhuis; Kristi L Mielke; Mihaela Cosma; Cacia Soares-Welch; Remberto Paulo; John M Miles; Cyril Y Bowers Journal: J Clin Endocrinol Metab Date: 2008-12-16 Impact factor: 5.958
Authors: J P Dias; D Melvin; E M Simonsick; O Carlson; M D Shardell; L Ferrucci; C W Chia; S Basaria; J M Egan Journal: Andrology Date: 2015-11-20 Impact factor: 3.842
Authors: Myong Kim; Jong Won Kim; Jong Keun Kim; Sang Mi Lee; Cheryn Song; In Gab Jeong; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn Journal: Cancer Med Date: 2018-07-10 Impact factor: 4.452